WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study

• Published in: Gynecologic oncology Vol. 174; pp. 239 - 246
• Main Authors: Embaby, Alaa, Kutzera, Joachim, Geenen, Jill J., Pluim, Dick, Hofland, Ingrid, Sanders, Joyce, Lopez-Yurda, Marta, Beijnen, Jos H., Huitema, Alwin D.R., Witteveen, Petronella O., Steeghs, Neeltje, van Haaften, Gijs, van Vugt, Marcel A.T.M., de Ridder, Jeroen, Opdam, Frans L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Carboplatin - therapeutic use; Carcinoma, Ovarian Epithelial - drug therapy; Cell Cycle Proteins - genetics; Disease-Free Survival; Female; Hematology, Oncology, and Palliative Medicine; Humans; Middle Aged; Obstetrics and Gynecology; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Protein-Tyrosine Kinases - antagonists & inhibitors; Tumor Suppressor Protein p53 - genetics

In the first part of this phase II study (NCT01164995), the combination of carboplatin and adavosertib (AZD1775) was shown to be safe and effective in patients with TP53 mutated platinum-resistant ovarian cancer (PROC). Here, we present the results of an additional safety and efficacy cohort and exp...